Other languages XOMA Corporation

Equities

XOMA

US98419J2069

Real-time Estimate Cboe BZX Other stock markets 02:35:25 2024-06-12 pm EDT			5-day change	1st Jan Change
25.2 ^USD	+5.02%		+1.68%	+33.78%

02:38pm	XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher	MT
May. 09	Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.	Apr. 29
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..	Apr. 02
XOMA Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08
Sector Update: Health Care Stocks Advance Friday Afternoon	Feb. 16
XOMA Agrees to Acquire Kinnate Biopharma	Feb. 16
XOMA Acquires Interest in Pain Management Medication Dsuvia for $8 Million	Jan. 18
XOMA Corporation acquired DSUVIA® of Talphera, Inc. for $8 million.	Jan. 17
XOMA Names Owen Hughes CEO, Jack Wyszomierski Chairman; to Make $1 Million Milestone Payment	Jan. 12
Xoma Names Owen Hughes as Chief Executive Officer	Jan. 08
Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors	Jan. 08
XOMA Authorizes $50 Million Share Buyback Program	Jan. 02
XOMA Authorizes $50 Million Share Buyback Program	Jan. 02
XOMA Corporation announces an Equity Buyback for $50 million worth of its shares.	Jan. 02
XOMA Corporation authorizes a Buyback Plan.	Jan. 01
Sector Update: Health Care Stocks Gain in Afternoon Trading	Dec. 19
Xoma Gets Up To $140 Million Royalty-Backed Loan From Blue Owl Capital; Xoma Shares Rise	Dec. 19
Xoma-Non-Dilutive, Non-Recourse, Royalty-Backed Loan For Up To $140 Million Of Capital	Dec. 19
XOMA Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
XOMA Earns $5 Million Milestone Upon US FDA Acceptance of Day One Biopharmaceuticals' NDA for Glioma Therapy	23-10-31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages XOMA Corporation

Equities

XOMA

US98419J2069

Other languages

Filters